| Literature DB >> 30375409 |
M Ribeiro-da-Silva1,2,3,4, D M Vasconcelos1,2, I S Alencastre1,2, M J Oliveira1,2, D Linhares3,4, N Neves1,2,3,4, G Costa3,4, R Henrique5,6, M Lamghari1,2,6, C J Alves7,8.
Abstract
Inflammation is a common symptom in joint disorders such as rheumatoid arthritis, osteoarthritis (OA) and implant aseptic loosening (AL). The sympathetic nervous system is well known to play a critical role in regulating inflammatory conditions, and imbalanced sympathetic activity has been observed in rheumatoid arthritis. In AL it is not clear whether the sympathetic nervous system is altered. In this study we evaluated the systemic and local profile of neuroimmune molecules involved in the interplay between the sympathetic nervous system and the periprosthetic inflammation in hip AL. Our results showed that periprosthetic inflammation does not trigger a systemic response of the sympathetic nervous system, but is mirrored rather by the impairment of the sympathetic activity locally in the hip joint. Moreover, macrophages were identified as key players in the local regulation of inflammation by the sympathetic nervous system in a process that is implant debris-dependent and entails the reduction of both adrenergic and Neuropetide Y (NPY)-ergic activity. Additionally, our results showed a downregulation of semaphorin 3A (SEMA3A) that may be part of the mechanism sustaining the periprosthetic inflammation. Overall, the local sympathetic nervous system emerges as a putative target to mitigate the inflammatory response to debris release and extending the lifespan of orthopedic implants.Entities:
Mesh:
Year: 2018 PMID: 30375409 PMCID: PMC6207762 DOI: 10.1038/s41598-018-33360-8
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1The systemic neuroimmune regulatory pathway was not targeted by periprosthetic inflammation in AL patients. The levels of norepinephrine, NPY and cortisol (a) and the levels of IL-6 (b) were evaluated by ELISA in the serum collected pre-operatively from OA and AL patients, and from healthy donors. The ratio serum cortisol/IL-6 was calculated (c). Results are presented as mean ± SEM, n = 13–15 for healthy donors and AO patients and n = 14–20 for AL patients. **p < 0.01; ****p < 0.001.
Figure 2Macrophages in AL periprosthetic tissues do not express TH or ADRB2. The expression of TH, ADRA1, ADRA2A and ADRB2 (a) and the expression of NPY and Y1R (b) by macrophages (CD68+) was evaluated in periprosthetic tissues from AL patients and in synovial tissues from OA patients through double immunohistochemistry staining. Macrophages expressing TH, ADRA1, ADRA2A, ADRB2 or NPY are highlighted with triangle head white arrows. Simple head white arrows indicate macrophages and white arrowheads highlight TH, ADRA1, ADRB2, NPY and Y1R staining in cells other than macrophages (positive control). Scale bar = 20 μm.
Figure 3The in vitro expression of ADRB2 is lower in M1 as compared with M2 macrophages. The in vitro mRNA expression of ADRB2 was evaluated in M0, M1 and M2 macrophages phenotypes. Results are represented as mean ± SEM, for n = 5 per group. Each symbol represents macrophages obtained from one specific blood donor. *p < 0.05.
Figure 4T cells express ADRA1 both in AL periprosthetic tissues and OA synovial membrane. The expression of TH, ADRA1, ADRA2A and ADRB2 (a), and the expression of NPY and Y1R (b) in T cells (CD3+) was evaluated in periprosthetic tissues from AL patients and in synovial tissues from OA patients through a double immunohistochemistry staining. T cells expressing TH or ADRA1 are highlighted with triangle head white arrows. Simple head white arrows indicate T cells and white arrowheads highlight ADRA1, ADRA2A, ADRB2, NPY and Y1R staining in cells other than T cells (positive control). Scale bar = 20 μm.
Figure 5B cells in AL periprosthetic tissues and OA synovial membrane do not express TH, ADRA1, ADRA2A, ADRB2, NPY or Y1R. The expression of TH, ADRB2, ADRA1 and ADRA2A (a), and the expression of NPY and Y1R (b) in B cells (CD20+) was evaluated in periprosthetic tissues from AL patients and in synovial tissues from OA patients through double immunohistochemistry staining. White arrows indicate B cells and white arrowheads highlight positive staining for TH, ADRA1, ADRA2A, ADRB2 and Y1R in cells other than B cells (positive control). Scale bar = 20 μm.
Figure 6Neurotrophins and semaphorins expression in AL periprosthetic tissues and OA synovial membrane. The mRNA levels of neurotrophins NGF and BDNF (a), and semaphorins SEMA3A, SEMA3C and SEMA3F (b) were assessed in OA synovial membrane and periprosthetic tissues from AL patients. Results are represented as mean ± SEM, for n = 8–9 per group. **p < 0.01, *p < 0.05.
Demographic data on included patients.
| N | Age (years) | Gender | |||
|---|---|---|---|---|---|
| Mean (±SD) | p | N of male/female | p | ||
| Group 1 Revision Surgery due to AL | 20 | 70.35 ± 11.4 | 0.119 | 6/14 | 0.537 |
| Group 2 Primary Surgery due to OA | 15 | 63.33 ± 14.5 | 6/9 | ||
| Group 3 Healthy Donors | 15 | 32.87 ± 3.4 | < 0.001* | 9/6 | |
AL- Aseptic loosening; OA- Osteoarthritis. *Comparing Group 3 with both Group 1 and Group 2.